ATE245437T1 - Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen - Google Patents

Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen

Info

Publication number
ATE245437T1
ATE245437T1 AT96909573T AT96909573T ATE245437T1 AT E245437 T1 ATE245437 T1 AT E245437T1 AT 96909573 T AT96909573 T AT 96909573T AT 96909573 T AT96909573 T AT 96909573T AT E245437 T1 ATE245437 T1 AT E245437T1
Authority
AT
Austria
Prior art keywords
endothelial cells
vascular endothelial
specific
growth factor
polypeptides
Prior art date
Application number
AT96909573T
Other languages
English (en)
Inventor
Ulf Eriksson
Birgitta Olofsson
Kari Alitalo
Katri Pajusola
Original Assignee
Ludwig Inst Cancer Res
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE245437(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/469,427 external-priority patent/US5607918A/en
Application filed by Ludwig Inst Cancer Res, Licentia Ltd filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE245437T1 publication Critical patent/ATE245437T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96909573T 1995-03-01 1996-03-01 Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen ATE245437T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39765195A 1995-03-01 1995-03-01
US08/469,427 US5607918A (en) 1995-03-01 1995-06-06 Vascular endothelial growth factor-B and DNA coding therefor
US08/569,063 US5928939A (en) 1995-03-01 1995-12-06 Vascular endothelial growth factor-b and dna coding therefor
PCT/US1996/002957 WO1996026736A1 (en) 1995-03-01 1996-03-01 Vascular endothelial growth factor-b

Publications (1)

Publication Number Publication Date
ATE245437T1 true ATE245437T1 (de) 2003-08-15

Family

ID=27410265

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96909573T ATE245437T1 (de) 1995-03-01 1996-03-01 Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen

Country Status (14)

Country Link
US (5) US5928939A (de)
EP (1) EP0814827B1 (de)
JP (2) JP3275024B2 (de)
CN (1) CN1146440C (de)
AT (1) ATE245437T1 (de)
AU (1) AU741856B2 (de)
CA (1) CA2211687C (de)
DE (1) DE69629181T2 (de)
DK (1) DK0814827T3 (de)
ES (1) ES2202432T3 (de)
NO (1) NO973933L (de)
NZ (1) NZ305091A (de)
PT (1) PT814827E (de)
WO (1) WO1996026736A1 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) * 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
DK0751992T3 (da) * 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US7160991B1 (en) * 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
WO1996027007A1 (en) * 1995-03-02 1996-09-06 Amrad Operations Pty. Ltd. A novel growth factor and a genetic sequence encoding same
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
CA2224002A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
PT848755E (pt) 1995-09-08 2003-12-31 Genentech Inc Proteina relacionada com o vegf
WO1997012972A2 (en) 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Regulated genes and uses thereof
WO1997017442A1 (en) 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
EP0956339B1 (de) 1996-08-23 2005-10-12 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
AU5439998A (en) * 1996-12-06 1998-06-29 Zymogenetics Inc. Vascular endothelial growth factor
EP0960334A1 (de) * 1996-12-20 1999-12-01 Ludwig Institute For Cancer Research Vegf-b/rezeptorkomplex und anwendung
DE69830320T2 (de) 1997-03-07 2006-02-02 The Wistar Institute Of Anatomy And Biology Verwendung von Adenoviralen Vektoren, die PDGF oder VEGF exprimieren, ZUR HEILUNG VON GEWEBSDEFEKTEN UND ZUR INDUZIERUNG DER HYPERVASKULITÄT IN SÄUGERGEWEBEN
NZ500530A (en) * 1997-04-25 2001-12-21 Collateral Therapeutics Truncated VEGF-B, VEGF-C, VEGF-3, PlGF, VRF-2, poxvirus ORF-1 and ORF-2 proteins
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
CN1295617A (zh) 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
JP2002534061A (ja) 1998-11-10 2002-10-15 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 血小板由来増殖因子ｄ、それをコードするｄｎａ、及びその利用法
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
EP1147193A4 (de) * 1999-01-29 2003-01-22 Ludwig Inst Cancer Res Von blutplättchen abstammender wachstumsfaktor-/vaskulärer endothel-wachstumsfaktor-ähnlicher wachstumsfaktor hund dessen anwendungen
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
WO2000052462A1 (en) * 1999-03-03 2000-09-08 Ludwig Institute For Cancer Research Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities
AU4662400A (en) * 1999-04-26 2000-11-10 Helsinki University Licensing Ltd Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
EP1183358A1 (de) * 1999-06-07 2002-03-06 Edwards Lifesciences Corporation Gezielte angiogenese
AU781084B2 (en) * 1999-07-28 2005-05-05 Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
EP1255560B1 (de) * 2000-02-02 2008-10-29 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
AUPQ568100A0 (en) * 2000-02-16 2000-03-09 Amrad Operations Pty. Limited A method for producing recombinant molecules
AU3988401A (en) * 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
AUPQ592100A0 (en) * 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
US20030104977A1 (en) * 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
CA2409948A1 (en) * 2000-05-17 2001-11-22 Xuri Li Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
US20020068694A1 (en) * 2000-07-26 2002-06-06 Jeltsch Markku Michael Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B
KR20020059609A (ko) * 2000-08-04 2002-07-13 벤슨 로버트 에이치. 혈관 내피 성장 인자 ２
AU2001296521A1 (en) * 2000-10-02 2002-04-15 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
US6793918B2 (en) * 2000-11-01 2004-09-21 Ludwig Institute For Cancer Research In vivo stimulation of angiogenic activity
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
WO2002046412A2 (en) * 2000-12-07 2002-06-13 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20070111944A1 (en) * 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20070050857A1 (en) * 2001-02-28 2007-03-01 Hayward Nick K Method of treatment and prophylaxis
AU2002303261A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US20030170786A1 (en) * 2001-04-13 2003-09-11 Rosen Craig A. Vascular endothelial growth factor 2
US20030176674A1 (en) * 2001-04-13 2003-09-18 Rosen Craig A. Vascular endothelial growth factor 2
JP2004536579A (ja) * 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050043227A1 (en) * 2001-04-24 2005-02-24 Veerle Compernolle Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
NZ529915A (en) * 2001-06-20 2007-07-27 Ludwig Inst Cancer Res Stimulation of vascularization of ischemic tissue by angiogenesis with VEGF-B186
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20100234570A1 (en) * 2001-06-28 2010-09-16 Domantis Limited Ligand
JP4303105B2 (ja) * 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
AU2002322461B2 (en) * 2001-07-12 2007-12-06 Vegenics Limited Lymphatic endothelial cells materials and methods
AU2002331669A1 (en) 2001-08-23 2003-03-10 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
CA2429483A1 (en) * 2002-05-17 2003-11-17 Amrad Operations Pty Ltd. Immunointeractive molecules
US20030235864A1 (en) * 2002-06-05 2003-12-25 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
EP1912069A3 (de) 2002-06-05 2008-07-09 Sopherion Therapeutics, Inc. Verfahren für Schirmliganden mit eukaryotischer Zellenanzeige
US20030232439A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
EP1545588A4 (de) 2002-07-23 2007-12-05 Ludwig Inst Cancer Res Verfahren und zusammensetzungen f r die aktivierung oder hemmung von vegf-d und vegf-c
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US20040258670A1 (en) * 2002-12-05 2004-12-23 Case Western Reserve University Cell-based therapies for ischemia
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
AU2004209668A1 (en) * 2003-02-04 2004-08-19 Flanders Interuniversity Institute For Biotechnology VEGF-B and PDGF modulation of stem cells
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
EP1560025A3 (de) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Marker spezifisch für Diabetes
CA2552241C (en) 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
WO2005084329A2 (en) * 2004-03-02 2005-09-15 Ludwig Institute For Cancer Research Method for inhibiting tumor formation and growth
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
ATE418346T1 (de) * 2004-04-08 2009-01-15 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
JP5014130B2 (ja) * 2004-08-02 2012-08-29 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． Ｖｅｇｆ−ｂアンタゴニストを含む癌治療方法
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
CA2599004C (en) 2005-02-28 2015-05-26 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
ES2363758T3 (es) * 2005-08-15 2011-08-16 Vegenics Pty Ltd Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
ES2429225T3 (es) 2006-05-17 2013-11-13 The Ludwig Institute For Cancer Research Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
US7819579B2 (en) * 2007-11-26 2010-10-26 Schmulenson Harold K Radiation sensing device and holder
WO2009075565A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
EP2271365A4 (de) * 2008-04-09 2011-10-26 Ludwig Inst Cancer Res Regulierung von fettsäuretransportern
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
KR101335203B1 (ko) * 2010-03-26 2013-11-29 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
RU2477529C2 (ru) * 2011-04-28 2013-03-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к эндотелиальной синтазе оксида азота человека
SI4374873T1 (sl) 2013-07-12 2026-01-30 Astellas Us Llc Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
CN105979965B (zh) * 2013-12-18 2021-07-09 杰特有限公司 治疗伤口的方法
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
US10745454B2 (en) * 2018-01-31 2020-08-18 Seyed Mohsen Asghari Method of synthesizing antagonist peptides for cell growth
CN109337931A (zh) * 2018-11-02 2019-02-15 东北师范大学 Vegfb基因的应用及vegfb肿瘤诱导和肿瘤抑制动物模型的构建方法
CN110777146A (zh) * 2019-11-28 2020-02-11 南通大学 一种pdgfb启动子活性报告质粒的构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
DK0751992T3 (da) * 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
WO1996027007A1 (en) * 1995-03-02 1996-09-06 Amrad Operations Pty. Ltd. A novel growth factor and a genetic sequence encoding same
CA2224002A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3

Also Published As

Publication number Publication date
EP0814827A4 (de) 1999-11-10
DK0814827T3 (da) 2003-11-10
EP0814827A1 (de) 1998-01-07
WO1996026736A1 (en) 1996-09-06
CA2211687C (en) 2011-05-24
EP0814827B1 (de) 2003-07-23
DE69629181T2 (de) 2004-05-13
PT814827E (pt) 2003-11-28
CA2211687A1 (en) 1996-09-06
JP3297687B2 (ja) 2002-07-02
ES2202432T3 (es) 2004-04-01
US6331301B1 (en) 2001-12-18
NO973933L (no) 1997-09-01
HK1008485A1 (en) 1999-07-30
NZ305091A (en) 1998-11-25
US5928939A (en) 1999-07-27
US7341996B2 (en) 2008-03-11
CN1176603A (zh) 1998-03-18
NO973933D0 (no) 1997-08-27
CN1146440C (zh) 2004-04-21
US20030170253A1 (en) 2003-09-11
JP3275024B2 (ja) 2002-04-15
JP2000228982A (ja) 2000-08-22
US20050064493A1 (en) 2005-03-24
DE69629181D1 (de) 2003-08-28
AU741856B2 (en) 2001-12-13
JPH10510718A (ja) 1998-10-20
AU5302196A (en) 1996-09-18
US5840693A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
DE69629181D1 (de) Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen
EP0956339A4 (de) Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
EP0653940A4 (de) Glialmitogene faktoren, ihre herstellung und verwendung.
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
AR021849A1 (es) Composiciones y metodos para la inmunoterapia especifica de wt1
IL193886A (en) Antibodies that bind to ldcam sequences
NO984415D0 (no) Peptider med antiproliferative egenskaper
DE69736432D1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DE69232309D1 (de) Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
CY1109518T1 (el) Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης
Kim et al. Incorporation of a ligand peptide for immune inhibitory receptor LAIR‐1 on biomaterial surfaces inhibits macrophage inflammatory responses
DE69229681D1 (de) Ein protein, das spezifische dna-strukturen erkennt, und seine verwendungen
LTIP1753A (en) Dna sequences coding for proteins, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
FI972170A7 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, n äitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
DK1212417T3 (da) Fremmelse eller inhibering af angiogenese og vaskularisering
ATE229074T1 (de) Rekombinante chladosporium herbarum allergene
DK0811068T3 (da) Humane DNase I varianter
SE0003099D0 (sv) Adhesive protein and uses therefore

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0814827

Country of ref document: EP